Clinical Trial Update: GALLANT 2 Tesaglitazar vs. Placebo [Phase 3]

View source ↗

Summary

A Phase 3 trial (GALLANT 2) evaluating tesaglitazar versus placebo in type 2 diabetes mellitus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tesaglitazar (tesaglitazar)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: TERMINATED